These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35046264)

  • 21. Sorafenib
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
    Ichida A; Akamatsu N; Nagata R; Mihara Y; Kawaguchi Y; Bae SK; Ishizawa T; Kaneko J; Arita J; Hasegawa K
    Anticancer Res; 2022 Feb; 42(2):1161-1167. PubMed ID: 35093921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.
    Sato A; Imai Y; Uchiya H; Uchida Y; Nakazawa M; Sugawara K; Nakayama N; Mochida S
    Intern Med; 2022 Aug; 61(15):2301-2305. PubMed ID: 35283380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma.
    Ikeda A; Aoki K; Kawamura M; Yamaguchi D; Kokuryu H
    Intern Med; 2021; 60(3):403-407. PubMed ID: 33518611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
    Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
    Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
    Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
    Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
    Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma.
    Sugimoto R; Inada H; Tanaka Y; Senju T; Aratake Y; Nakanishi A; Miki M; Lee L; Hisano T; Matsumoto Y; Mano Y; Iguchi T; Sugimachi K; Okumura Y; Taguchi K; Furukawa M
    Clin J Gastroenterol; 2021 Oct; 14(5):1484-1490. PubMed ID: 34176067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenvatinib mesylate to treat hepatocellular carcinoma.
    Ielasi L; Tovoli F; Piscaglia F
    Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
    Yamaoka K; Kodama K; Hiramatsu A; Ando Y; Kosaka Y; Suehiro Y; Fujii Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Imamura M; Takahashi S; Chayama K; Aikata H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1685-1693. PubMed ID: 33326154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2089-2093. PubMed ID: 32234901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
    Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
    Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.
    Kohya R; Sugiura R; Yamamoto Y; Naruse H; Hatanaka K; Kinoshita K; Abiko S; Miyamoto S; Suzuki K; Kushibiki H; Munakata S; Shimoyama N
    Intern Med; 2023 Apr; 62(7):995-998. PubMed ID: 36047124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
    Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
    Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects.
    Takagi H; Kaji K; Nishimura N; Ishida K; Ogawa H; Takaya H; Kawaratani H; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Cells; 2021 Mar; 10(3):. PubMed ID: 33807929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
    Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
    Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
    Bai Y; Hu X; Ren Z; Hisai T; Yusa W; Weng L; Shiba S; Takase T
    Future Oncol; 2022 Jul; 18(22):2413-2424. PubMed ID: 35674480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.